
Wockhardt divests its Veterinary business to Vétoquinol

Mumbai, August 20, 2009

Pharmaceutical and biotechnology major Wockhardt Limited today announced the completion of the divestment of its Animal Health Division to Vétoquinol, France. A postal ballot to the shareholders approved the divestment of Wockhardt's Animal Health Division and with the receipt of the necessary administration approvals the transaction is now complete.

Wockhardt is re-inventing itself by taking fundamentally strong and positive steps towards its continued growth plan.

About Wockhardt

Wockhardt is a technology-driven global pharmaceutical and biotechnology major with an innovative multi-disciplinary research and development programme. It has 5 research centres and 14 world-class manufacturing plants dotting various countries and continents that are compliant to international regulatory standards such as the US FDA, MHRA and other global regulatory bodies. It has end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API's, the dosage forms and marketing through its wholly owned subsidiary in the US. Wockhardt has a global footprint including the US, UK, Ireland and France with a multi-ethnic workforce from 14 different nationalities.